Waldencast plc operates as a global multi-brand beauty and wellness platform built around Obagi Medical and Milk Makeup. News about WALD commonly covers brand-level product launches, physician-dispensed skincare, cosmetics, suncare, and aesthetic offerings, including Obagi's advanced skincare products and Obagi® saypha® MagIQ™ hyaluronic acid filler.
Company updates also include quarterly and annual financial results, segment performance, channel and distribution developments, clinical-evidence collaborations for aesthetic products, supply-chain and credit-facility actions, and governance or reporting matters tied to financial restatements, internal control over financial reporting, and regulatory review.
Obagi Medical (NASDAQ: WALD) launched a two-step Lip Therapy protocol on February 3, 2026: Lip Therapy AHA + PHA Smoothing Micro-Peel ($55) and Soothe & Protect Lip Treatment SPF 30 ($40). The regimen pairs nightly chemical resurfacing with daily hydration and SPF to improve texture, hydration, and fine lines.
Products are available through professional channels now and on Obagi.com beginning February 3, 2026. Consumer perception testing reported immediate and two-week improvements in hydration and appearance.
Obagi Medical (NASDAQ: WALD) announced a collaboration with VIO Med Spa as a launch partner in the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™. The multi-site program will collect standardized clinical and patient-experience data across VIO’s national franchise and begin with 2 days of expert-led VIO University training.
The initiative combines Obagi protocols with VIO’s injectable expertise to evaluate performance, usability, and patient outcomes for the MACRO Core Technology hyaluronic acid filler.
Obagi Medical (NASDAQ: WALD) announced a collaboration with Next Health for the ALOHA Program to generate real-world evidence on Obagi® saypha® MagIQ™. The multi-site evaluation will collect standardized clinical and patient-experience data across Next Health locations and share initial findings at leadership meetings and industry conferences.
The program integrates injectables with holistic wellness protocols to assess performance in longevity-focused clinical settings.
Waldencast (NASDAQ: WALD) brands Obagi Medical and Alpha Aesthetics Partners launched the ALOHA Program to generate real-world evidence for Obagi® saypha® MagIQ™, Obagi’s first FDA‑approved injectable hyaluronic acid filler. Alpha, selected as the ALOHA launch partner, will run a structured, multi-site evaluation across its network (31 locations in 12 states) with standardized data collection. Initial findings will be presented at the upcoming Alpha Summit and shared at industry conferences. The program focuses on clinical performance, patient experience, and integrating Obagi protocols to support providers and consistent outcomes.
Waldencast (NASDAQ: WALD) announced that Obagi Medical has launched the ALOHA Real-World Program with Platinum Dermatology Partners as the initial launch partner to generate real-world evidence for Obagi saypha MagIQ. The program will provide Platinum providers hands-on use of the injectable, standardized data capture across multiple practices, and a structured evaluation of complete Obagi protocols. Initial findings are slated for presentation at Platinum’s annual Summit in Dallas in September 2026 and at key industry conferences to demonstrate real-world outcomes and support the product’s differentiated launch strategy.
Obagi Medical (NASDAQ: WALD) launched the ALOHA (Aesthetic Leadership with Obagi Hyaluronic Acid) Program on January 21, 2026 to collect structured real‑world, practice‑focused evidence for the rollout of Obagi® saypha® MagIQ™. The product is described as the company's first FDA‑approved injectable hyaluronic acid filler with claimed features including high usable HA content on injection, consistent gel distribution, and predictable injection force and swelling profile. ALOHA will gather standardized injector and practice owner feedback to inform post‑launch education, scientific content, and broader adoption and is positioned to become the largest real‑world evaluation of a newly launched HA injectable.
Waldencast (NASDAQ: WALD) reported Q2 2025 and H1 2025 results and provided a Q3 2025 trading update on Nov 24, 2025. Q2 2025 net revenue was $66.8M (+5.6% YoY) with Adjusted EBITDA margin of 5.0%. H1 2025 net revenue was $132.3M (+0.5% YoY) and net loss was $185.2M, driven by goodwill impairments of $132.1M (Obagi) and $20.0M (Milk Makeup). Q3 2025 net revenue was $67.8M (‑3.4% YoY); Obagi Medical grew to $42.6M (double‑digit) while Milk Makeup declined to $25.2M.
Strategic moves include FDA approval of Obagi Saypha MagIQ filler, acquisition of Novaestiq, sale of Obagi Japan trademark for $82.5M, credit facility refinancing, and a strategic review led by Lazard.
Obagi Medical (NASDAQ: WALD) presented new clinical data at the American Society for Dermatologic Surgery Annual Meeting, Nov 13–16, 2025 in Chicago.
Key highlights: Obagi saypha ChIQ pivotal randomized multicenter trial showed non-inferiority to Juvéderm Voluma XC for midface augmentation with high patient satisfaction and robust safety across diverse skin types; the abstract was selected as a top 10 oral presentation. Interim 3-month data for Nu-Cil BioStim Scalp Serum reported improvements in scalp health and hair appearance. saypha ChIQ is under FDA review; Obagi saypha MagIQ is FDA approved.
Waldencast (NASDAQ: WALD) announced a $82.5 million sale of its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical and a new $225 million secured, three-year first-lien term loan facility with funds managed by Lumina Capital, with proceeds expected by Nov 17, 2025.
The company said Rohto previously paid royalties equal to 3% of net revenue to Waldencast for Obagi Medical in fiscal 2024. Waldencast intends to use most of the Rohto proceeds to repay a significant portion of the Lumina loan, repay existing facilities, and fund working capital and general corporate purposes. Lazard acted as financial advisor.
Waldencast (NASDAQ: WALD) said it expects to report Second Quarter Fiscal 2025 results and Q3 2025 financial results on November 24, 2025. The company indicated it does not plan to host a conference call for these releases due to an ongoing strategic review. Investors should watch the November 24 date for published results and any follow-up communications the company may provide after its strategic review concludes.